PTN Share Price | Palatin Technologies, Inc. Stock Analysis & Recommendation

Q: How big is Palatin Technologies, Inc.?

Market Cap: As of Jun 18, Palatin Technologies, Inc. has a market capitalization of 5.25 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.35 million and a net profit of -23.32 million.Balance Sheet Snapshot: As of June 2024, the company's shareholder's funds stood at -0.11 million, while total assets were reported at 10.74 million.

Q: What does Palatin Technologies, Inc. do?

Overview:Palatin Technologies, Inc. is a biopharmaceutical company engaged in developing targeted therapeutics that modulate the melanocortin and natriuretic peptide receptor systems, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)Market cap: USD 5.25 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: 0.36Return on Equity: 365.24%Price to Book: -0.82Contact Details:Address: 4B Cedarbrook Dr, CRANBURY NJ: 08512-3641Tel: 1 609 4952200Website: https://www.palatin.com/

Q: Is Palatin Technologies, Inc. overvalued or undervalued?

As of 13 February 2025, the valuation grade for Palatin Technologies, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its negative valuation ratios, including a Price to Book Value of -0.73, an EV to EBIT of -0.09, and an EV to EBITDA of -0.09, which suggest that the company is struggling financially compared to its peers. In comparison, KALA BIO, Inc. has a P/E ratio of -2.7752 and Entera Bio Ltd. shows a P/E of -8.6141, both reflecting similarly poor financial health. Palatin's stock has underperformed significantly against the S&P 500, with a year-to-date return of -84.68% compared to the S&P 500's 12.22%, reinforcing the notion that the stock is not a viable investment at its current valuation.

Q: Is Palatin Technologies, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Palatin Technologies, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD also reflects a mildly bullish stance. However, the daily moving averages indicate a bearish trend. The Bollinger Bands show a mildly bullish signal on the weekly chart but are bearish on the monthly chart. The KST is bullish on the weekly timeframe but bearish monthly, and the Dow Theory indicates a mildly bearish stance weekly with no trend monthly. In terms of performance, Palatin has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -84.68% versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed indicators and substantial underperformance relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.95 k

Shareholding (Dec 2025)

FII

0.15%

Held by 9 FIIs

DII

97.14%

Held by 3 DIIs

Promoter

0.00%

How big is Palatin Technologies, Inc.?

22-Jun-2025

As of June 18, Palatin Technologies, Inc. has a market capitalization of 5.25 million, categorizing it as a Micro Cap company, with net sales of 0.35 million and a net profit of -23.32 million for the latest four quarters. As of June 2024, shareholder's funds were -0.11 million, and total assets were 10.74 million.

View full answer

What does Palatin Technologies, Inc. do?

22-Jun-2025

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted therapeutics that affect the melanocortin and natriuretic peptide receptor systems. It operates as a micro-cap company with a market cap of $5.25 million and reported a net profit loss of $5 million as of March 2025.

View full answer

Who are in the management team of Palatin Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of Palatin Technologies, Inc. includes Dr. John Prendergast (Independent Chairman), Dr. Carl Spana (President and CEO), and several Independent Directors: Mr. Robert deVeer, Dr. Alan Dunton, Mr. Joseph Hull, Dr. Anthony Manning, and Ms. Arlene Morris. They oversee the company's strategic direction and governance.

View full answer

Is Palatin Technologies, Inc. overvalued or undervalued?

20-Sep-2025

As of February 13, 2025, Palatin Technologies, Inc. has deteriorated to a "does not qualify" valuation grade due to negative financial ratios and a year-to-date return of -84.68%, indicating it is overvalued and not a viable investment compared to its peers and the S&P 500.

View full answer

Is Palatin Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Palatin Technologies, Inc. shows a mildly bullish technical trend, with mixed indicators and significant underperformance of -84.68% year-to-date compared to the S&P 500's 12.22%.

View full answer

Compare Palatin Technologies, Inc. with Similar Stocks

Entera Bio Ltd.Acasti Pharma, Inc.Alzamend Neuro, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 40 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.24

Return on Equity

-83.97%

Price to Book

3.48

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

36.82%

6 Months

98.91%

1 Year

-42.89%

2 Years

-75.01%

3 Years

547.34%

4 Years

-96.01%

5 Years

-97.96%

Palatin Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

59.77%

EBIT Growth (5y)

9.19%

EBIT to Interest (avg)

-17.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.36

Sales to Capital Employed (avg)

1.62

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

10.35%

ROCE (avg)

ROE (avg)

8.56%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.48

EV to EBIT

-2.05

EV to EBITDA

-2.07

EV to Capital Employed

-9.19

EV to Sales

2.86

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-83.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (2.72%)

Foreign Institutions

Held by 9 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -204.17% vs 69.23% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.30",
          "val2": "-4.90",
          "chgp": "-48.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.30",
          "val2": "-2.40",
          "chgp": "-204.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-63,157.50%",
          "val2": "0.00%",
          "chgp": "-6,315.75%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is -100.00% vs -8.16% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 41.75% vs -8.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "4.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.40",
          "val2": "-29.60",
          "chgp": "24.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-7.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.30",
          "val2": "-29.70",
          "chgp": "41.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-6,743.30%",
          "chgp": "674.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-7.30

-4.90

-48.98%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.30

-2.40

-204.17%

Operating Profit Margin (Excl OI)

-63,157.50%

0.00%

-6,315.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -204.17% vs 69.23% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

0.00

4.50

-100.00%

Operating Profit (PBDIT) excl Other Income

-22.40

-29.60

24.32%

Interest

0.00

Exceptional Items

0.00

-7.70

100.00%

Consolidate Net Profit

-17.30

-29.70

41.75%

Operating Profit Margin (Excl OI)

0.00%

-6,743.30%

674.33%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is -100.00% vs -8.16% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 41.75% vs -8.00% in Jun 2024

All Annual Results

Company CV

About Palatin Technologies, Inc.

Palatin Technologies, Inc.

Pharmaceuticals & Biotechnology

Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

Company Coordinates

Company Details

4B Cedarbrook Dr , CRANBURY NJ : 08512-3641

Tel: 1 609 4952200

https://www.palatin.com/

Registrar Details